Test Page

27.03.24

Press Release

UPDATE ON AUSTRALIA’S LARGEST PSYCHEDELICS TRIAL FOCUSED ON TREATMENT RESISTENT DEPRESSION

12.03.24

Press Release

UNIVERSITY OF WESTERN AUSTRALIA DISCOVERS NEW LSD COMPOUNDS

14.07.23

Press Release

ETHICS APPROVAL RECEIVED FOR WORLD FIRST PHASE II TRIAL

03.03.23

Media

Australia is about to legalise MDMA and psilocybin for medicinal use. So how will it work?

16.02.23

Press Release

Woke Enters Clinical Agreement with Curtin University to Evaluate WP002 Psilocybin for Chronic Pain

06.02.23

Press Release

Woke Welcomes Psilocybin Down-Scheduling

30.01.23

Media

Australia’s biggest research trial using psychedelics to treat depression | Swinburne University of Technology

22.12.22

Media

Trial to explore the use of psychedelics for alcohol use disorder

20.12.22

Press Release

Woke and Curtin University Sign Letter of Intent for Phase II trial of WP002 Psilocybin in Chronic Pain

19.12.22

Press Release

Woke Enters Clinical Agreement with QIMR Berghofer to Evaluate WP002 Psilocybin for Prolonged Grief

12.12.22

Press Release

Woke and University of Sydney Sign Clinical Trial Agreement for Phase IIB trial of WP002 Psilocybin in Alcohol Use Disorder

21.10.22

Media

Biotech Daily: Dr Boreham's Crucible on Woke

18.10.22

Press Release

Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder

10.10.22

Media

Woke setting sights on Australian IPO in 2023

19.08.22

Press Release

Provisional Patent Application

16.08.22

Press Release

Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression

12.08.22

Press Release

Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief

04.08.22

Media

Potential Therapeutic Benefits of Psychedelics

04.08.22

Press Release

Woke Highlights Morgan Stanley Report on Psychedelics

11.07.22

Media

Can microdosing psychedelics improve your mental health? Here's what the science says

13.06.22

Media

Elon Musk has joined the celebrity support for psychedelics

10.06.22

Media

Woke and UWA enter agreement to identify novel LSD analogues

08.06.22

Press Release

Woke and University of Western Australia collaborate to discover LSD analogues

03.06.22

Press Release

WokePh and Monash complete WP001 psilocybin formulation

19.05.22

Media

Could psychedelic drugs be the key to treating mental health issues?

04.05.22

Press Release

Woke Announces First Shipment of Natural Health Products from HAVN Life Sciences

27.04.22

Media

Macquarie University media release regarding clinical trial with Woke

27.04.22

Press Release

Woke Enters Clinical Agreement with Macquarie University for WP001 Low-dose Psilocybin for Moderate Depression

07.04.22

Press Release

Woke Signs Manufacturing Agreement with IDT Australia for Novel Psilocybin Formulations to Treat Depression

03.03.22

Press Release

Woke Expands Partnership with Monash University to Develop Novel Psilocybin Formulation for Treatment- Resistant Depression

16.02.22

Press Release

Woke Signs Letter of Intent with The University of Western Australia to Identify Novel LSD Analogues

03.02.22

Press Release

Woke Imports Psilocybin from Purisys in the US for Formulation of Novel Dosage Forms

02.02.22

Press Release

Woke Signs Letter of Intent with IDT Australia for Manufacture of Novel Psilocybin Dosage Forms

01.02.22

Press Release

Woke Pharmaceuticals Launches New Website

17.01.22

Media

CY2022 CEO Corporate Overview

17.12.21

Press Release

Woke’s Response to TGA Decision to Maintain the Current Schedule 9 Classification for Psilocybin

15.11.21

Press Release

Woke Completes Oversubscribed $1.55m Seed Capital Raising to Develop Medicinal Psychedelics

14.11.21

Press Release

Woke Purchases Synthetic Psilocybin from Purisys for Formulation of Novel Dosage Forms

07.11.21

Press Release

Woke and HAVN Life Enter into Agreement to Distribute Natural Health Products in AU, NZ and China

04.11.21

Press Release

Woke Joins Medical Psychedelics Working Group of UK Drug Science

19.10.21

Press Release

UPDATE ON AUSTRALIA’S LARGEST PSYCHEDELICS TRIAL FOCUSED ON TREATMENT RESISTENT DEPRESSION

UNIVERSITY OF WESTERN AUSTRALIA DISCOVERS NEW LSD COMPOUNDS

ETHICS APPROVAL RECEIVED FOR WORLD FIRST PHASE II TRIAL

Australia is about to legalise MDMA and psilocybin for medicinal use. So how will it work?

Woke Enters Clinical Agreement with Curtin University to Evaluate WP002 Psilocybin for Chronic Pain

Woke Welcomes Psilocybin Down-Scheduling

Australia’s biggest research trial using psychedelics to treat depression | Swinburne University of Technology

Trial to explore the use of psychedelics for alcohol use disorder

Woke and Curtin University Sign Letter of Intent for Phase II trial of WP002 Psilocybin in Chronic Pain

Woke Enters Clinical Agreement with QIMR Berghofer to Evaluate WP002 Psilocybin for Prolonged Grief

Woke and University of Sydney Sign Clinical Trial Agreement for Phase IIB trial of WP002 Psilocybin in Alcohol Use Disorder

Biotech Daily: Dr Boreham's Crucible on Woke

Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder

Woke setting sights on Australian IPO in 2023

Provisional Patent Application

Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression

Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief

Potential Therapeutic Benefits of Psychedelics

Woke Highlights Morgan Stanley Report on Psychedelics

Can microdosing psychedelics improve your mental health? Here's what the science says

Elon Musk has joined the celebrity support for psychedelics

Woke and UWA enter agreement to identify novel LSD analogues

Woke and University of Western Australia collaborate to discover LSD analogues

WokePh and Monash complete WP001 psilocybin formulation

Could psychedelic drugs be the key to treating mental health issues?

Woke Announces First Shipment of Natural Health Products from HAVN Life Sciences

Macquarie University media release regarding clinical trial with Woke

Woke Enters Clinical Agreement with Macquarie University for WP001 Low-dose Psilocybin for Moderate Depression

Woke Signs Manufacturing Agreement with IDT Australia for Novel Psilocybin Formulations to Treat Depression

Woke Expands Partnership with Monash University to Develop Novel Psilocybin Formulation for Treatment- Resistant Depression

Woke Signs Letter of Intent with The University of Western Australia to Identify Novel LSD Analogues

Woke Imports Psilocybin from Purisys in the US for Formulation of Novel Dosage Forms

Woke Signs Letter of Intent with IDT Australia for Manufacture of Novel Psilocybin Dosage Forms

Woke Pharmaceuticals Launches New Website

CY2022 CEO Corporate Overview

Woke’s Response to TGA Decision to Maintain the Current Schedule 9 Classification for Psilocybin

Woke Completes Oversubscribed $1.55m Seed Capital Raising to Develop Medicinal Psychedelics

Woke Purchases Synthetic Psilocybin from Purisys for Formulation of Novel Dosage Forms

Woke and HAVN Life Enter into Agreement to Distribute Natural Health Products in AU, NZ and China

Woke Joins Medical Psychedelics Working Group of UK Drug Science

Woke Collaborates with Monash University to Develop Novel Psilocybin Formulation for Moderate Depression